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Abstract
Background: FTY720 (fingolimod, Gilenya™) is a daily oral therapy for multiple sclerosis that readily accesses the
central nervous system (CNS). FTY720 is a structural analog to the sphingolipid sphingosine-1-phosphate (S1P) and
is a cognate ligand for the S1P G-protein coupled receptors (S1PR). Studies in experimental autoimmune
encephalomyelitis using mice with conditionally deleted S1P1R from astrocytes indicate that one beneficial effect of
FTY720 in this model is via downregulating external receptors, which inhibits responses induced by the natural
ligand. Another proposed effect of FTY720 on neuroinflammation is its ability to maintain persistent signaling in
cells via internalized S1P1R resulting in functional responses that include suppressing intracellular calcium release.
We used human fetal astrocytes to investigate potential dual inhibitory- and function-inducing effects of daily
FTY720 on responses relevant to neuroinflammation. For the inhibitory effects, we used signaling and proliferation
induced by the natural ligand S1P. For the function-inducing responses, we measured inhibition of intracellular
calcium release stimulated by the proinflammatory cytokine, interleukin (IL)-1β.
Methods: Astrocytes derived from human fetal CNS specimens and maintained in dissociated cultures were
exposed to 100 nM of the biologically active form of FTY720 over a dosing regimen that ranged from a single
exposure (with or without washout after 1 h) to daily exposures up to 5 days. Responses measured include:
phosphorylation of extracellular-signal-regulated kinases (pERK1/2) by Western blotting, Ki-67 immunolabeling for
cell proliferation, IL-1β-induced calcium release by ratiometric fluorescence, and cytokine/chemokine (IL-6, CXCL10)
secretions by ELISA.
Results: We observed that a single addition of FTY720 inhibited subsequent S1PR ligand-induced pERK1/2 signaling
for >24 h. Daily FTY720 treatments (3-5 days) maintained this effect together with a loss of proliferative responses
to the natural ligand S1P. Repeated FTY720 dosing concurrently maintained a functional cell response as measured
by the inhibition of intracellular calcium release when stimulated by the cytokine IL-1β. Recurrent FTY720
treatments did not inhibit serum- or IL-1β-induced pERK1/2. The secretions of IL-6 and CXCL10 in response to IL-1β
were unaffected by FTY720 treatment(s).
Conclusion: Our results indicate that daily FTY720 exposures may regulate specific neuroinflammatory responses by
desensitizing astrocytes to external S1PR stimuli while sustaining cellular influences that are independent of new
surface S1PR activation.
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Background
FTY720 is a clinically approved daily oral therapy used
to prevent disease relapses in multiple sclerosis (MS)
[1]. FTY720 is a structural analog of the bioactive lipid
sphingosine-1-phosphate (S1P) and is a cognate ligand
for the G-protein coupled S1P1, 3, 4, 5 receptors (S1PR)
[1]. The therapeutic effect of FTY720 is currently
attributed to the drug’s ability to internalize S1PR
(mainly the Gi-coupled S1P1R) on lymphocytes, which
results in the cells being unresponsive to the natural
ligand S1P, and thus they cannot exit from regional
lymph nodes [2].
FTY720 differs from other approved immunomodu-
latory MS therapies in that it readily accesses the cen-
tral nervous system (CNS), raising the issue of what
functional effects it may have on tissue injury and
repair-related processes within the CNS [3]. Intracere-
bral injections of FTY720 reduced disease severity in
the experimental autoimmune encephalomyelitis (EAE)
mice independent of systemic lymphopenia [4]. More-
over, systemic administrations of FTY720 to immunodefi-
cient animals enhanced functional recovery following
traumatic spinal cord injury [5]; of note is that the effects
in both animal models implicate drug interactions with
S1PR expressed by astrocytes. It remains unclear, however,
if the observed tissue protection/repair processes are the
results of inhibiting astrocyte responses to the natural lig-
and and/or inducing cellular signaling. Previous studies
measuring the phosphorylation of extracellular-signal-
regulated kinases (pERK1/2) indicate that astrocytes
show robust signaling to S1P and FTY720 via S1P1R
engagement [6,7]. The finding that mice lacking S1P1R
expression on astrocytes experienced a decreased sever-
ity in clinical EAE [8] suggests that a potential benefit
of FTY720 on CNS inflammation is by inhibiting
extracellular S1P signaling on astrocytes. However, zu
Heringdorf et al. demonstrated that activating S1P1R
in stably transfected (non-neural) cell lines negatively
regulates intracellular calcium (Ca2+) release and such
a release could have a number of neuroinflammation-
relevant consequences including mitochondrial stress,
production of free radicals, and proteases/phospholi-
pases activation [9,10].
The fate of internalized S1P receptors upon exposure
to FTY720 differs from that resulting from interacting
with the natural ligand S1P [11]. Receptors internalized
consequent to FTY720 binding can persist in intracellu-
lar vesicular compartments rather than rapidly recycling
to the cell surface as seen with the natural ligand [6].
Using a number of cell lines transfected with S1P1R
and primary cell types (including rodent astrocytes),
Mullershausen et al. showed that signaling by internal-
ized S1P1R persists for hours following a single 1-h
pulse of FTY720 [6].
Here we applied an experimental regimen of FTY720
on astrocytes derived from the fetal human CNS to
model the daily clinical use of the agent. We studied
how FTY720 could influence neuroinflammation-
relevant responses via its dual role in inhibiting surface
S1PR signaling and proliferation while sustaining active
responses in the cells as measured by the inhibition of
intracellular calcium release when stimulated by the
cytokine interleukin (IL)-1β.
Methods
Isolation of human fetal astrocytes and cell culture
CNS tissues were obtained from the human fetal tissue
repository (Albert Einstein College of Medicine, Bronx,
NY), and experiments were carried out with guide-
lines approved by McGill University and the Canadian
Institutes for Health Research (CIHR). Cells were isolated
as previously described by Williams et al. [12]. Briefly, fetal
brain tissue (15–18 gestational weeks) was minced and
treated with DNase (Roche, Nutley, NL) and trypsin
(Invitrogen, Carlsbad, CA) before being passed through a
nylon mesh. The flow through was plated at 106 cells/ml
in high glucose Dulbecco’s modified essential medium
(DMEM; Sigma, Oakville, ON) supplemented with 10%
fetal calf serum (FCS) (v/v), penicillin/streptomycin and
glutamine (all from Invitrogen, Burlington, ON). Cells
were grown in a humidified incubator maintained at 37°C,
5% CO2 and passaged every 14 days. To ensure cell purity,
all experiments were conducted on the third or fourth
passage. More than 98% of cells were GFAP positive as
determined by flow cytometry (Figure 1A and B). For
serum-free assays, astrocyte media was changed to
DMEM-F12 (DMEM; Sigma, Oakville, ON) with 1%
bovine serum albumin (Invitrogen, Burlington, ON), peni-





diol) was provided by Novartis, Basel, Switzerland. In all
of the experiments, the phosphorylated form of FTY720
was used. Powdered FTY720 was reconstituted in di-
methyl sulfoxide hydrochloric acid (DMSO-HCl) (50mM),
aliquoted and stored at −20°C until used. Cells were
treated with 100 nM FTY720 in all of the experiments.
Initial dose response studies were conducted using
FTY720 over a range of 10–1,000 nM (with cell toxicity
becoming measurable at the high dose).
Sphingosine-1-phosphate
S1P (Sigma, Oakville, ON) was dissolved in 100% methanol,
aliquoted and stored at −20°C until use. A final concentra-
tion of 100 nM S1P was used in all of the experiments.
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S1PR-activated pERK1/2 studies
Astrocytes were seeded in six-well plates and cultured to
80% confluency. To assess pERK1/2 responses to
FTY720, S1P, IL-1β (10 ng/ml recombinant human IL-
1β; PeproTech, Montreal, QC) or 10% FCS (v/v), astro-
cytes were placed in serum-free DMEM for 6 h and then
treated with the stimulus for 15 min. Following stimula-
tion, cells were washed with phosphate-buffered saline
(PBS), and whole-cell lysates were collected in 200 μl of
RIPA buffer (1% SDS, 1% deoxycholate, 1% Igepal, 150
mM NaCl, 50 mM Tris) with Baculogold protease
inhibitor (BD Biosciences, Mississauga, ON) and phos-
phatase inhibitor (1 mM Na3VO4; Sigma, Oakville, ON).
Samples were stored at −80°C until assayed.
Western blotting
Polyvinylidene difluoride membranes were immunoblotted
with anti-phospho-ERK1/2 antibody (monoclonal rabbit
anti-mouse antibodies 1:1,000; Cell Signaling Technology,
Danvers, MA) and detected using horseradish peroxidase-
conjugated secondary antibodies (1:1,000; Calbiochem, San
Diego, CA) and enhanced chemiluminescence plus re-
agents (GE Healthcare, Piscataway, NJ). Membranes were
then stripped with Reblot (Millipore, Billerica, MA) and re-
probed for loading control (anti-β-actin; 1:1,000, Invitrogen
or anti-total ERK1/2; 1:1,000 StressGen, Victoria, BC).
Protein band intensities were quantified using ImageJ soft-
ware (National Institutes of Health), and the data reported
are expressed as relative fold change to untreated controls.
Proliferation assays
A total of 5 × 104 cells per well were plated in 48-well
plates. To determine the proportion of astrocytes under-
going mitotic cell division at the time points indicated
(see Results), astrocytes were stained with anti-Ki-67
antibody (1:100, rabbit FITC-conjugated; Millipore, Billerica,
MA) and with Hoechst dye to label cell nuclei (1:10,000;
Invitrogen, Burlington, ON). Images were taken from
16 fields per well and analyzed using MetaXpress
cellular imaging analysis software using the cell-
scoring module (Molecular Devices, Sunnyvale, CA).
Quantitative output measures by MetaXpress proces-
sing were used to calculate proliferation rate indices
where the proportion of astrocytes positive for Ki-67
was determined as a function of total cell number per
field (Hoechst).
Effects of FTY720 on pERK1/2 and proliferation studies
In the studies examining the effects of FTY720 on astro-
cytes signaling and proliferation, FTY720 or S1P was
added either at the outset of the culture (with or without
washout after 1 h) or daily for 3-5 days. For the pERK1/
2-related studies, the above treated cells were re-
challenged after 1, 3 or 5 days with FTY720 for 15 min.
For the proliferation assays, astrocytes were treated
with FTY720 or S1P for 24 h before washout with
PBS 3×. S1P was given to astrocytes immediately
following washout for an additional 24 h prior to fixing
with 4% paraformaldehyde (Sigma, Oakville, ON) and
immunostaining for Ki-67.
IL-1β Ca2+ mobilization studies
To test the whether FTY720 could actively regulate Ca2+
mobilization in astrocytes, IL-1β (10 ng/ml recombinant
human IL-1β, dissolved in Ca2+-free PBS; PeproTech,
Montreal, QC) was used as a stimulus for Ca2+ release
from internal stores. Astrocytes were plated at a high
density of 2 × 105 cells/ml in 96-well plates and cultured
in DMEM-F12 medium for up to 5 days under the dif-
ferent FTY720 exposure regimens outlined previously in
Figure 1 More than 98% of the cell culture is GFAP positive. (A) Flow cytometry dot plot showing >98% of cells positive for the FITC-labeled
GFAP marker. (B) Histogram demonstrating the rightward shift for the GFAP + signal compared to isotype control.
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Figure 2 (See legend on next page.)
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the signaling-related (pERK1/2) studies. Following FTY720
treatment(s), astrocytes were washed with Ca2+-free PBS
and subsequently loaded with a calcium-sensitive fluores-
cent dye fura-2 AM (5μM, Molecular Probes) suspended
in Ca2+-free Ringer’s solution (130 mM NaCl, 3 mM KCl,
1 mM MgCl2, 10 mM HEPES, pH 7.4) for 45 min in a hu-
midified chamber at 37°C, 5% CO2. Cells were washed 2×
with Ca2+-free PBS to remove extracellular fura-2 AM and
incubated in Ca2+-free Ringer’s solution for an additional
30 min at room temperature to allow complete hydrolysis
of acetoxymethyl esters before imaging. The Wallac Victor3
(Perkin-Elmer, Wellesley, MA) fluorescent microplate
reader was used to measure ratiometric intracellular Ca2+
concentrations. IL-1β was loaded in the integrated injector
and delivered at a volume of 25 μl/well. To establish base-
line values, five fluorescent ratio measurements were taken
before the IL-1β injection, and 30 subsequent recordings
were made immediately following IL-1β delivery into each
well. Data reported represent means from three independ-
ent experiments with each observation averaged over at
least eight wells per condition. Fluorescence emission
ratios are expressed as intracellular Ca2+ values using
the formula described by Grynkiewicz et al. [13]. Magni-
tudes of response (to the IL-1β agonist) were calculated by
measuring the difference between peaks of Ca2+ curves
with baseline values.
Cytokine/chemokine production
To assess whether FTY720 exposure(s) on astrocytes
affect their productions of cytokines/chemokines (in re-
sponse to IL-1β stimulation) and whether FTY720 itself
induces IL-6 and CXCL10 (IP-10), astrocytes were
treated with FTY720 ± IL-1β. For the + IL-1β condi-
tions, astrocytes were stimulated with IL-1β for 24 h be-
fore collecting supernatants. The levels of IL-6 and
CXCL10 present in supernatants were measured in du-
plicates using ELISA plates following the manufacturer’s
instructions (BD Biosciences, Mississauga, ON).
Statistical analyses
Statistical analyses were performed with Prism 5 (GraphPad
Software). One-way analysis of variance (ANOVA) with
Bonferroni post hoc tests was used to compare mean
values. Significance was accepted at the p < 0.05 level
(*p < 0.05; **p < 0.01; ***p < 0.001). The number of in-
dividual studies performed for each set of experiments
is indicated in the Results section and in figure legends.
Results
S1P receptor-dependent effects of FTY720 and S1P
For these studies, we measured pERK1/2 activation and
proliferation responses following either a single dosage
of FTY720 or repeated daily administrations.
Single exposure studies
pERK1/2 activation
As shown in Figure 2Ai (and in Additional file 1), pERK1/
2 signaling was evident in astrocytes exposed to FTY720
or S1P at 15 min, as previously reported in Durafourt
et al. [14] and Mullershausen et al. [6]. ERK1/2 phosphor-
ylation induced by either FTY720 or S1P was blocked by
adding 10 μM of the mitogen-activated protein kinase/
ERK kinase (MEK) inhibitor U0126 (Promega) (Figure
2Aii). When astrocytes were incubated overnight (18 h)
with an initial dose of FTY720, the intensity of pERK1/2
signaling evoked by a new 15-min FTY720 challenge was
reduced compared to cells maintained in serum-free cul-
ture medium (Figure 2B). Similar reductions were noted
when S1P was used as stimulus (15 min) (Additional file 2).
Cells cultured with S1P overnight showed a pERK1/2
response comparable to control cells when challenged
with FTY720 (Additional file 3). Figure 2C shows the
inhibited pERK1/2 response by FTY720 pre-exposure
fully recovered by 72 h following initial treatment.
S1P-induced proliferation
As illustrated in Figure 3A (and quantified in Figure 3B),
S1P overnight elicited a 1.8-fold increase in astrocyte
(See figure on previous page.)
Figure 2 (A) Human fetal astrocytes respond to FTY720 or S1P exposure by signaling through the ERK1/2 pathway. (i) Astrocytes were
exposed to FTY720 or S1P for 15 min. Western blot: untreated (−); S1P vehicle (v); S1P (S) (100 nM); FTY720 vehicle (v); FTY720 (F) (100 nM). S1P
and FTY720 induced significant pERK1/2 at 15 min. Total ERK1/2 was used as the loading control. Quantified band intensity relative to untreated
control (n = 3). (ii) Activation signals by FTY720 and S1P are dependent on MEK1/2. MEK inhibitor was applied to astrocytes with FTY720 or S1P
for 15 min. Western blot lanes: 1, untreated (−); 2, MEK inhibitor; 3, FTY720 (F); 4, FTY720 plus MEK inhibitor; 5, S1P (S); 6, S1P plus MEK inhibitor.
The MEK inhibitor itself did not induce notable pERK1/2. When the MEK inhibitor was applied with FTY720 or S1P, pERK1/2 signals induced by
either ligand were comparable to the untreated control. Total ERK1/2 was used as the loading control. (B) FTY720 treatment overnight inhibits
pERK1/2 activation by subsequent FTY720 exposure. FTY720 (F) (15 min) induced significant pERK1/2 in untreated (−) astrocytes and those pre-
treated overnight with the vehicle (v). Pre-treating astrocytes with FTY720 overnight resulted in a blunted pERK1/2 signal upon re-challenge with
FTY720 (15 min). β-Actin was used as the loading control. Quantified band intensity relative to untreated control (n = 3). (C) Recovery of pERK1/2
response at 72 h following initial FTY720 exposure. FTY720 (F) (15 min) induced significant pERK1/2 in untreated astrocytes (−) and those pre-
treated with a single dose of FTY720 or vehicle (v) for 72 h. Recovery of pERK1/2 activation by FTY720 was achieved by 72 h following initial
FTY720 treatment. β-Actin was used as the loading control. Quantified band intensity relative to untreated control (n = 3).
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proliferation as measured by the percentage of cells posi-
tive for Ki-67 (nuclear protein, marker for proliferation
[15]). Astrocytes incubated overnight with FTY720 did
not produce a similar proliferation effect. Figure 3C
shows the proliferation rates of astrocytes to S1P when
pre-exposed with S1P or FTY720 overnight (Day 0).
Initial Day 0 treatment with S1P increased astrocyte pro-
liferation (1.6-fold increase), whereas FTY720 was com-
parable to basal proliferation rates (i). Subsequent (Day 1)
S1P stimulation for 24 h increased astrocyte proliferation
in cells maintained in culture medium alone (1.5-fold
increase) or pre-treated with S1P (ii). Astrocytes exposed
to FTY720 overnight on Day 0 did not demonstrate a pro-
liferative response to the S1P given on Day 1.
The above results suggest that a single treatment with
FTY720 desensitizes cell surface S1P receptors for >24 h.
Extended treatment studies
pERK1/2 signaling
As shown in Figure 4, astrocytes treated with FTY720
daily for 5 days (or 3 days, Additional file 4A) showed a
reduced pERK1/2 response to the FTY720 challenge (15
min) compared to astrocytes maintained in culture
medium alone (untreated control). pERK1/2 signals in as-
trocytes treated with FTY720 only at the initiation of cell
culture (either left in or washed after 1 h) were compar-
able to the untreated controls. Addition of serum to astro-
cyte cultures treated once or repeatedly with FTY720
provoked a robust increase in pERK1/2, indicating the
preserved integrity of this signaling pathway in the cells
(Additional file 4B).
These above results suggest that repeated daily treat-
ment with FTY720 sustains desensitization of cell surface
S1P receptors.
Functional effects of FTY720
To assess the capacity of FTY720 to mediate a functional
effect in astrocytes, we examined inhibition of Ca2+
mobilization in these cells. Figure 5A presents the magni-
tude of Ca2+ mobilization in astrocytes stimulated with
IL-1β. As shown in Figure 5A and B, repeated daily treat-
ments with FTY720 (e.g., the condition that desensitizes
S1P receptors) were able to abrogate the Ca2+ efflux in-
duced by IL-1β stimulation. There was no inhibition of
IL-1β-induced Ca2+ mobilization after 5 days in astrocyte
cultures exposed to a single dose of FTY720 given at the
outset. However, an apparent partial inhibition of Ca2+ re-
lease was observed at the initial overnight time point
(See figure on previous page.)
Figure 3 (A) Human fetal astrocyte proliferation in response to S1P receptor ligands. Immunocytochemistry stains for astrocytes
undergoing cell division (Ki-67, red) and cell nuclei (Hoechst nuclear stain, blue). (i) Untreated cells (basal proliferation). (ii) FTY720 (100 nM)
overnight. (iii) S1P (100 nM) overnight. (iv) DMSO control. (v) Methanol control (MeOH). (B) Quantification of human fetal astrocyte proliferation in
response to S1P receptor ligands. Proliferation indices were generated by determining the percentage of cells positive for Ki-67 relative to total cell
population (Hoechst nuclear stain). Fold changes in proliferation were calculated relative to rate of proliferation under basal conditions. S1P
induced a 1.8-fold increase in astrocyte proliferation, whereas FTY720 did not mediate proliferation beyond the basal rate (normalized to 1)
(n = 3). (C) FTY720 pre-incubation blocks proliferative response of S1P on human fetal astrocytes. At outset (Day 0), astrocytes were either treated
with S1P (S) or FTY720 (F). Following overnight culture, cells were either (i) left untreated (−) or (ii) incubated with S1P for another 24 h (Day 1).
Proportion of astrocytes undergoing proliferation (Ki-67+) was then determined. Hoechst nuclear stain was used to determine total cell number.
Proliferation fold change was calculated relative to rate of proliferation under basal conditions (normalized to 1). (i) S1P induced a 1.6-fold
increase in astrocyte proliferation whereas FTY720 was comparable to basal proliferation rate. (ii) Significant proliferation (1.5-fold increase) was
observed in untreated astrocytes (Day 0) when given S1P for 24 h (Day 1). S1P-pre-treated astrocytes on Day 0 continued to proliferate (1.8-fold
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Figure 4 Repeated (daily) FTY720 administration sustains the
inhibition of pERK1/2 response. pERK1/2 levels in response to
FTY720 (F) (100 nM) for 15 min in astrocytes that were initially
exposed to a single dose of FTY720 (F) or vehicle (v) with washout
after 1 h (1 h), or without washout (1×) or repeated daily for 5 days
(5×). pERK1/2 activation by FTY720 was observed in the 1-h and
single without-washout conditions, but not in the repeated daily
FTY720 condition. β-Actin was used as the loading control.
Quantified band intensity relative to untreated control (n = 3).
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following exposure to FTY720 (Additional file 5). Neither
FTY720 nor S1P themselves induced significant Ca2+ re-
lease in astrocytes when compared to their vehicles
(changes from baseline were: FTY720 468 ± 193 nM
versus vehicle 942 ± 434 nM; S1P 463 ± 171 nM versus
vehicle 443 ± 94 nM, n = 5 separate experiments). As
shown in Figure 5Ci and Cii, FTY720 added either once
or daily for 3 days did not significantly block IL-
1β-induced productions of IL-6 or CXCL10 (IP-10), and
FTY720 itself did not stimulate IL-6 or CXCL10 release.
Furthermore, FTY720 did not affect the IL-1β-induced
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Figure 5 (A) Repeated FTY720 administrations inhibit IL-1β-induced Ca2+ mobilization in human fetal astrocytes. Representative traces
showing daily FTY720 for 5 days inhibited IL-1β (10 ng/ml)-induced Ca2+ mobilization; this effect was not seen with FTY720 (1× FTY720) or
vehicle (1× vehicle) added only at outset of the culture, nor with the vehicle control added daily for 5 days (5× vehicle). (B) Bar graph showing
the mean (±SEM) changes in Ca2+ mobilization under conditions described in (A). *Signifies comparison between FTY720 (5×) and vehicle (5×)
(n = 3). (C) Pre-treatment of human fetal astrocytes with FTY720 does not alter IL-6 or CXCL10 (IP-10) secretions induced by IL-1β. Astrocytes pre-
treated with either FTY720 (F) or with the vehicle (v) control at outset of culture (1×) or daily for three cycles (3×). After the 72-h culture, IL-1β
(10 ng/ml) was added and cells were cultured for an additional 24 h before collecting supernatants (n = 3). (i) Astrocytes produced significant
levels of IL-6 in response to IL-1β activation. Levels of IL-6 produced were not affected by FTY720 pre-treatment(s), and FTY720 itself did not
induce significant IL-6 secretion. (ii) Astrocytes produced significant levels of CXCL10 (IP-10) response to IL-1β activation. Pre-treating astrocytes
with FTY720 did not alter CXCL10 secretion induced by IL-1β, and FTY720 itself did not induce CXCL10 secretion (n = 3).
Wu et al. Journal of Neuroinflammation 2013, 10:41 Page 8 of 11
http://www.jneuroinflammation.com/content/10/1/41
These results indicate that repeated daily applications of
FTY720 mediate specific functional responses in astro-
cytes even when cell surface receptors are desensitized.
Discussion
In the current study, we demonstrate that repeated daily
FTY720 administrations can evoke dual effects on astro-
cytes, both of which may be relevant to the modulation
of neuroinflammatory responses by this compound. We
initially show that FTY720 desensitizes responses that
are dependent on surface S1PR signaling including
FTY720 and S1P ligand-induced ERK1/2 phosphoryl-
ation and S1P-induced proliferation. We did not observe
astrocyte proliferation with FTY720 even though astro-
cyte proliferation is attributed to S1P1R activation
[7,16,17] and existing data suggest that FTY720 predom-
inantly activates S1P1R [18]. Astrocyte proliferation is a
histological feature of active neuroinflammatory condi-
tions [reviewed in Pekny and Nilsson (2005)] and would
be predicted to be associated with the production of
multiple molecules that regulate or mediate inflamma-
tory responses [19].
Our observations follow up on the studies of
Mullershausen et al. who utilized labeled receptors
transfected in cell lines to track receptor localization
(cell membrane vs. internalized) after exposure to
FTY720 or S1P [6]. Their study showed that at 5 h after
exposure to FTY720, the S1P receptors are internalized
and plasma membrane-dependent signaling responses to
FTY720 or S1P are reduced (referred to as receptor
desensitization) [6]. They showed that under such condi-
tions there was persistent signaling via the internalized
receptors [6]. We now show that daily FTY720
maintains this dual effect of desensitizing membrane-
dependent signaling while permitting internal receptor-
dependent responses.
Differential processing of internalized S1P receptors by
FTY720 versus the natural ligand S1P is well described
in cell line transfection studies using labeled receptors
[11,20]. Oo et al. found that FTY720 results in vesicular
storage of receptors prior to ubiquitination and degrad-
ation, whereas S1P induces rapid re-cycling to the cell
surface [11]. We now demonstrate that repeated daily
application of FTY720 maintains this surface receptor
desensitization, which results in the loss of both pERK1/2
activation to external FTY720/S1P and proliferation to
S1P. Such astrocytes, however, do retain their capacity to
respond to non-S1PR-mediated stimuli and signal through
the ERK1/2 pathway as shown by the robust pERK1/2
response to serum and IL-1β.
In the absence of surface S1PR-dependent signaling
and proliferation, we demonstrate that FTY720 can con-
tinue to exert a functional response in human astrocytes.
As mentioned, FTY720 mainly binds S1P1R [7,16,17],
and zu Heringdorf et al. have previously shown that
ongoing S1P1R stimulation inhibited the ATP-evoked
calcium release by activating PKCα and PKCβI, negative-
regulators of PLC [21]. We measured the extent of intra-
cellular calcium inhibition in cells treated with FTY720
and used the proinflammatory cytokine IL-1β to stimulate
the release of intracellular calcium stores in such cells.
This calcium-inhibitory effect persisted when FTY720 was
applied daily over the course of 5 days, whereas astrocytes
given a single application of FTY720 at the outset of treat-
ment responded to IL-1β by releasing significant levels of
calcium. IL-1-receptor activation on astrocytes leads to
signaling through the NF-kB pathway and triggers the
release of calcium from intracellular stores [21-23]. Acti-
vation of calcium-signaling pathways in response to IL-1β
stimulation could have a number of functional conse-
quences, including mitochondrial stress, production of
free radicals and proteases/phospholipases activation [10].
The inhibition of calcium release by daily FTY720 treat-
ments did not impair astrocytes’ production of the cyto-
kine IL-6 or the chemokine CXCL10 (IP-10) in response
to IL-1β. While both FTY720 and S1P have been reported
to increase intracellular calcium levels [6], we did not ob-
serve direct calcium mobilization from cultured astrocytes
in response to either of the ligands.
Conclusion
In this study, we investigated the functional effects of
repeated daily doses of FTY720 on human fetal astrocytes
in vitro. We showed the potential of daily FTY720 in
desensitizing astrocytes from surface receptor-dependent
signaling by measuring pERK1/2 activation and prolifera-
tion induced by the natural ligand S1P. We also showed
that daily FTY720 sustained an inhibition effect on calcium
release upon IL-1β stimulation. Collectively, our data indi-
cate that FTY720 can mediate dual neuroinflammation-
relevant effects on astrocytes by inhibiting external S1P re-
ceptor activation while sustaining internal S1PR-signaling
influences.
Additional files
Additional file 1: Colocalization of GFAP and pERK1/2 in astrocyte
culture. Immunocytochemistry labeling: (A-D) Untreated; (E-H)
vehicle; (I-L) FTY720 (100 nM). Scale bar = 10 μm. Merged images
show the colocalization of pERK (red) signal with GFAP + (green) cells.
Most abundant pERK signal is observed in the FTY720-treated condition.
Nuclear DAPI stain (blue).
Additional file 2: FTY720 treatment overnight inhibits pERK1/2
signaling by subsequent S1P stimulation. S1P (S) (100 nM) and
FTY720 (F) (100 nM) stimulation for 15 min induced significant pERK1/2 in
untreated (−) astrocytes. Pre-treating astrocytes with FTY720 overnight
resulted in a blunted pERK1/2 signal upon re-exposure to either FTY720
or S1P for 15 min. Total ERK1/2 was used as the loading control.
Additional file 3: S1P treatment overnight does not inhibit pERK1/2
activation by subsequent FTY720 exposure. FTY720 (F) (100 nM)
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stimulation for 15 min induced significant pERK1/2 in untreated (−)
astrocytes and in astrocytes pre-treated overnight with S1P (S) (100 nM).
β-Actin was used as the loading control.
Additional file 4: (A) Repeated (daily) FTY720 administration for 3
days sustains the inhibition of pERK1/2 response. pERK1/2 levels in
response to FTY720 (F) (100 nM) for 15 min in astrocytes that were
initially exposed to a single dose of FTY720 with washout after 1 h (1h),
or without washout (1×), or repeated daily for 3 days (3×). pERK1/2
activation by FTY720 was observed in the 1-h and the single without
washout conditions but not in the repeated daily FTY720 condition.
β-Actin was used as the loading control. (B) FTY720 treatment does not
inhibit pERK1/2 induction by serum. pERK1/2 levels in response to 10%
fetal calf serum for 15 min in astrocytes that were initially exposed to a
single dose of FTY720 (1×) or repeated daily for 3 days (3×). pERK1/2
activation by 10% serum was observed in all of the pre-treatment
conditions. β-Actin was used as the loading control.
Additional file 5: FTY720 overnight treatment inhibits IL-1β
-induced Ca2+ mobilization in human fetal astrocytes. Overnight
treatment with FTY720 (100 nM) inhibited IL-1β (10 ng/ml)-induced Ca2+
mobilization compared to vehicle control.
Additional file 6: S1P or FTY720 treatment overnight does not
affect IL-1β activation of pERK1/2. IL-1β (10 ng/ml) stimulation for 15
min induced significant pERK1/2 in untreated (−) astrocytes and in those
pre-treated overnight with S1P (S) (100 nM) or FTY720 (F) (100 nM). Total
ERK1/2 was used as the loading control.
Abbreviations
Ca2+: Calcium; CNS: Central nervous system; CXCL10: C-X-C motif chemokine
10; FTY720: 2-amino-2-[2-(4-octyl-phenyl)ethyl]-1, 3-propanediol
hydrochloride; HFA: Human fetal astrocytes; IL-1β: Interleukin-1 beta;
IL-6: Interleukin-6; IP-10: Interferon gamma-induced protein 10; MS: Multiple
sclerosis; pERK1/2: Phospho-extracellular signal-regulated kinases1/2;
PKC: Protein kinase C; PLC: Phospholipase C; S1P: Sphingosine-1-phosphate;
S1PR: Sphingosine-1-phosphate receptor.
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